SEC Form 4 · accession 0001209191-15-032415
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J. Fitzpatrick
Officer — Chief Financial Officer
Period of report
Apr 1, 2015
Accepted (ET)
Apr 3, 2015 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $26.00 | Apr 1, 2015 | A | 40,000 | A | — | Apr 1, 2025 | Common Stock | 40,000 | 40,000 | D |
| Stock Option (right to buy)F3,F4 | — | Apr 1, 2015 | A | 10,000 | A | — | — | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the fair market value of the closing price of the Issuer on the date of the grant.
- F225% of the shares of common stock underlying this stock option award will vest on April 1, 2016. The remaining 75% of the shares of common stock underlying this stock option award will vest thereafter in equal monthly installments through April 1, 2019, subject to the Reporting Person's continued employment with the Issuer.
- F3Each restricted stock unit represents a contingent right to receive one share of common stock.
- F4The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on April 1, 2016, 33.33% of the units vesting on April 1, 2017, and 33.33% of the units vesting on April 1, 2018, subject to the Reporting Person's continued employment with the Issuer.